Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Zaviralci angiogeneze v zdravljenju možganskih tumorjev
Authors:ID Ocvirk, Janja (Author)
Files:.pdf PDF - Presentation file, download (443,02 KB)
MD5: 6C1AADEE0CF7B416FF9B8DBA4487F618
PID: 20.500.12556/dirros/cb2f8461-521d-457c-a837-d375802357b6
 
Language:Slovenian
Typology:1.04 - Professional Article
Organization:Logo OI - Institute of Oncology
Abstract:Maligni gliomi so po histologiji in po odgovoru na zdravljenje heterogena skupina možganskih tumorjev. Standardno zdravljenje glioblastomov je kombinacija obsevanja in konkomitantne kemoterapije s temozolomidom. Antiangiogena strategija predstavlja nov pristop v zdravljenju malignih gliomov, saj so to zelo dobro ožiljeni tumorji. Predklinični podatki kažejo, da je rast teh tumorjev močno odvisna od nastajanja novih žil, te pa spodbujajo dejavniki, ki jih izloča tumor, med njimi tudi endotelni žilni rastni dejavnik (VEGF). Bevacizumab je humanizirano monoklonsko protitelo, ki veže VEGF in je dokazano učinkovit pri številnih solidnih tumorjih. V monoterapiji ali v kombinaciji s citostatiki je učinkovit tudi v zdravljenju glioblastomov, kar so pokazali rezultati kliničnih raziskav. Skupaj z učinkovitostjo zdravljenja se izboljšajo kognitivne funkcije, zmanjša se potreba po kortikosteroidih in izboljša se kakovost življenja. Bevacizumab predstavlja novo možnost zdravljenja bolnikov, pri katerih se glioblastom ponovi oz. napreduje.
Publication status:Published
Publication version:Version of Record
Year of publishing:2009
Number of pages:str. 127-129, 153
Numbering:Letn. 13, št. 2
PID:20.500.12556/DiRROS-8638 New window
UDC:616.831-006.6-085
ISSN on article:1408-1741
URN:URN:NBN:SI:doc-34GBY615
COBISS.SI-ID:855419 New window
Copyright:by Authors
Publication date in DiRROS:31.08.2018
Views:3995
Downloads:730
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:Angiogenesis Inhibitors in Brain Tumor Treatment
Abstract:Considering the histology of malignant gliomas and their response to treatment, they are regarded as a heterogenous group of brain tumors. Standard treatment is a combination of irradiation and concomitant chemotherapy with temozolomide. A new approach to the treatment of malignant gliomas is antiangiogenic strategy because these tumors are highly vasculated. Preclinical data show that the growth of these tumors depends on the onset of new blood vessels which is stimulated by various factors, such as VEGF (vascular endothelial growth factor), produced by the tumor itself. Bevacizumab is a humanized monoclonal antibody that binds to VEGF. It has been proved to be efficient the treatment of numerous solid tumors. Moreover, bevacizumab is efficient also in the treatment of glioblastomas, applied as monotherapy or in combination with cytostatics, which has been confirmed by the results of several clinical studies. In addition to its efficiency in the treatment glioblastomas, it has also been found to have the capacity of improving the patients' cognitive functions, reducing their need for corticosteroids, thereby also improving their quality of life. Bevacizumab offers a new potential in the treatment of recurrent or advanced glioblastoma.


Archive

niGradiv

Back